SCHEMBL6314059

SCHEMBL6314059

COc1ccc2cc(Nc3nc(N)ncc3-c3cc(OC)c(OC)c(OC)c3)cnc2c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FYN P06241 3/20 0.44
IGF1R P08069 2/20 0.43
EGFR P00533 3/20 0.43
LCK P06239 2/20 0.43
EPHB4 P54760 1/20 0.41
GAK O14976 2/20 0.40
RIPK2 O43353 1/20 0.40
COQ8A Q8NI60 1/20 0.40
NLK Q9UBE8 1/20 0.40
INSR P06213 1/20 0.40
MET P08581 1/20 0.40
CDK2 P24941 1/20 0.40
KDR P35968 1/20 0.40
TEK Q02763 1/20 0.40
PDGFRB P09619 2/20 0.40
PDGFRA P16234 2/20 0.40
DHFR P00374 2/20 0.40
ALPL P05186 2/20 0.39
PIK3CA P42336 1/20 0.39
LMNA P02545 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6314442 0.92 EGFR (0.45) FYNIGF1REGFRLCKEPHB4
SCHEMBL6313257 0.86 GAK (0.46) FYNIGF1REGFRLCKGAK
SCHEMBL6313711 0.84 PIK3CA (0.41) PDGFRBPDGFRADHFRALPLPIK3CA
SCHEMBL6312059 0.83 ALPL (0.44) FYNIGF1REGFRLCKGAK
SCHEMBL31180290 0.77 BRAF (0.51) FYNEGFRLCKGAKCDK2
SCHEMBL28037971 0.77 PRMT7 (0.49) FYNEPHB4DHFRPIK3CABRAF
SCHEMBL6313459 0.76 PIK3CA (0.41) EGFRLCKPDGFRBPDGFRADHFR
SCHEMBL6315310 0.75 ADORA1 (0.45) IGF1REGFRGAKINSRMET
SCHEMBL6313634 0.74 ALPL (0.49) IGF1RALPLPIK3CALMNASMN1; SMN2
SCHEMBL6314480 0.73 IGF1R (0.46) IGF1REGFRKDRPDGFRBALPL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6939874-B2 Substituted pyrimidinyl derivatives and methods of use AMGEN INC. (US) 2005-09-06 US disclosed
US-20040063705-A1 Substituted pyrimidinyl derivatives and methods of use AMGEN INC. 2004-04-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040063705-A1 Substituted pyrimidinyl derivatives and methods of use DPYD, TYMP, TPMT FYN 1254/4885IGF1R 4054/4885EGFR 1302/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.